Skip to main content
FOR HEALTHCARE PROFESSIONALS ONLY
Home
Articles
Sanofi branded clouded background image

Latest Articles

Type 1 diabetes autoantibodies article category image
Article
Jun 22, 2026

Type 1 Diabetes Autoantibodies: Early Detection and Risk Prediction

Autoimmune type 1 diabetes (T1D) is a lifelong autoimmune condition marked by progressive beta cell reduction. Autoantibodies targeting pancreatic islet antigens emerge months to years before clinical onset.1 The presence of autoantibodies signifies immune system dysregulation and facilitates the identification of individuals in the early stages of autoimmune T1D.2 This transformation enables predictive screening and timely intervention for individuals at risk.3

Learn more
Rising incidence of autoimmune T1D category image
Article
Jun 22, 2026

Rising incidence of autoimmune T1D: Need for screening

Type 1 diabetes (T1D) is an autoimmune condition marked by reduction in insulin-producing β-cells, leading to an absolute or near-absolute insulin deficiency. The increasing incidence of autoimmune T1D in populations with relatively stable genetic backgrounds suggests that environmental factors are playing an increasingly important role in triggering β-cell-specific autoimmunity or accelerating the progression of autoimmune T1D.1 Screening for autoimmune T1D-associated autoantibodies represents a reliable method for identifying individuals in the presymptomatic stage, before significant β-cell loss and need for exogenous insulin therapy. Early identification of individuals with an increased chance of having autoimmune T1D enables timely monitoring and interventions, which can reduce the chance of experiencing a medical emergency like diabetic ketoacidosis (DKA).2

Learn more
Latest guideline updates in autoimmune T1D article category image
Article
Jun 22, 2026

Latest guideline updates in autoimmune T1D screening and monitoring

Recent updates from International Society for Pediatric and Adolescent Diabetes (ISPAD) 2024, American Diabetes Association (ADA) 2026, and International Consensus Report 2024 introduce important refinements to autoimmune type 1 diabetes (T1D) management protocols.1-3 These evidence-based enhancements provide healthcare providers (HCPs) with clearer pathways for screening, staging, and monitoring—addressing key barriers to screening adoption.1-3

Learn more
Doctor giving high five to a child wit his mother watching
Article
Jun 22, 2026

Autoimmune Diseases and Type 1 Diabetes: Understanding the Connection

Autoimmune diseases and autoimmune type 1 diabetes (T1D) are deeply connected through shared genetic pathways, creating a significant yet underrecognized risk. Emerging evidence shows that individuals with autoimmune thyroid disease or celiac disease face a substantially higher risk of developing autoimmune T1D. As research highlights important risk factors for type 1 diabetes, proactive screening and risk assessment have become increasingly important to reduce preventable complications and improve patient outcomes.1

Learn more
Genetic Risk for Autoimmune Type 1 Diabetes category image
Article
Jun 22, 2026

Genetic Risk for Autoimmune Type 1 Diabetes: Why Screening Should Extend Beyond First-Degree Relatives

The landscape of autoimmune type 1 diabetes (T1D) screening is evolving rapidly; it is driven by evidence that genetic risk extends well beyond the immediate family.1,2 While healthcare professionals (HCPs) have long recognized the elevated risk among first-degree relatives; emerging research reveals a more complex genetic basis that necessitates broader screening approaches for effective early identification and improved patient outcomes.3-5

Learn more
Article
Dec 1, 2025

Early identification of autoimmune type 1 diabetes can reduce its psychological impact.

Psychological issues in autoimmune patients with type 1 diabetes (T1D) impact glycemic control, increase the risk of cardiovascular complications, contribute to comorbid psychosocial conditions, and reduce overall quality of life.1 Early screening for genetic risk factors and beta-cell autoantibodies helps prevent severe complications, such as diabetic ketoacidosis (DKA) and ensures timely access to crucial psychosocial support.2

Learn more
Article
Dec 1, 2025

Early screening for autoimmune T1D: A paradigm shift in disease management

The ongoing paradigm shift in autoimmune type 1 diabetes (autoimmune T1D) care with early screening and risk monitoring can now help identify people at risk in the pre-symptomatic stages.1 The HCPs can be instrumental in enabling this shift by supporting knowledge dissemination and clinical application by early screening of autoimmune T1D.1,2 This approach ensures that benefits are realized by patients and caregivers at the early stage of autoimmune T1D.1,2

Learn more
123